Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 19/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL747312 | 0.87 | GRM2 (0.48) | GRM2HTR2AAVPR1A | |
| SCHEMBL749290 | 0.85 | GRM2 (0.62) | GRM2HTR2A | |
| SCHEMBL748760 | 0.83 | GRM2 (0.65) | GRM2AVPR1A | |
| SCHEMBL6927583 | 0.80 | GRM2 (0.65) | GRM2HTR2A | |
| SCHEMBL749092 | 0.79 | GRM2 (0.54) | GRM2AVPR1A | |
| SCHEMBL749926 | 0.79 | GRM2 (1.00) | GRM2HTR2A | |
| SCHEMBL751971 | 0.79 | GRM2 (0.51) | GRM2HTR2A | |
| SCHEMBL748378 | 0.78 | GRM2 (0.66) | GRM2 | |
| SCHEMBL748341 | 0.77 | GRM2 (0.73) | GRM2HTR2A | |
| SCHEMBL750682 | 0.76 | GRM2 (0.60) | GRM2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11369606-B2 | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use | JANSSEN PHARMACEUTICA NV (BE) | 2022-06-28 | — | — | US | disclosed |
| US-20220143141-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-12 | — | — | US | disclosed |
| US-20220047593-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-17 | — | — | US | disclosed |
| EP-3827830-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | Janssen Pharmaceutica NV (BE) | 2021-06-02 | — | — | EP | disclosed |
| US-20200138814-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-07 | — | — | US | disclosed |
| US-20200138813-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-07 | — | — | US | disclosed |
| EP-3431106-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | Janssen Pharmaceutica NV (BE) | 2019-01-23 | — | — | EP | disclosed |
| EP-3424535-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | Janssen Pharmaceutica NV (BE) | 2019-01-09 | — | — | EP | disclosed |
| US-10071095-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders | Janssen Pharmaceuticals, Inc. (US) | 2018-09-11 | — | — | US | disclosed |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | JANSSEN PHARMACEUTICALS INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-8937060-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals, Inc. (US) | 2015-01-20 | — | — | US | disclosed |
| EP-2430022-B1 | 1,2,4-Triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders | JANSSEN PHARMACEUTICALS INC (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20120184525-A1 | 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THIER USE FOR THE TREATMENT OF PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ADDEX PHARMA S.A. (CH) | 2012-07-19 | — | — | US | disclosed |
| US-20120184525-A1 | 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THIER USE FOR THE TREATMENT OF PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ADDEX PHARMA S.A. (CH) | 2012-07-19 | — | — | US | disclosed |
| US-20120184525-A1 | 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THIER USE FOR THE TREATMENT OF PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ADDEX PHARMA S.A. (CH) | 2012-07-19 | — | — | US | disclosed |
| EP-2430022-A1 | 1,2,3-TRIAZOLO Ý4,3-A¨PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | Janssen Pharmaceuticals, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010130424-A9 | 1,2,4-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2010130424-A9 | 1,2,4-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2010130424-A1 | 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010130424-A1 | 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10071095-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders | GRM2, GRM1, GRIA2 | GRM2 1/4885HTR2A 42/4885AVPR1A 463/4885 |
| US-20120184525-A1 | 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THIER USE FOR THE TREATMENT OF PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GRM2, GRM3, GRM1 | GRM2 1/4885HTR2A 47/4885AVPR1A 540/4885 |
| US-20220047593-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | GRM2, GRIN2A, GRIK2 | GRM2 1/4885HTR2A 29/4885AVPR1A 143/4885 |
| US-20170333426-A1 | 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders | GRM2, GRM1, GRIN2C | GRM2 1/4885HTR2A 43/4885AVPR1A 491/4885 |
| US-20200138813-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | GRM2, GRIN2A, GRIK2 | GRM2 1/4885HTR2A 29/4885AVPR1A 143/4885 |
| US-11369606-B2 | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use | GRM2, GRIN2A, GRIK2 | GRM2 1/4885HTR2A 29/4885AVPR1A 143/4885 |
| US-20200138814-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | GRM2, GRIN2A, GRIK2 | GRM2 1/4885HTR2A 29/4885AVPR1A 143/4885 |
| US-20220143141-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | GRM2, GRIN2A, GRIK2 | GRM2 1/4885HTR2A 29/4885AVPR1A 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.